I am always a little unsure about these 2 vaccines
so here is a cheat sheet
Pneumococcus Currently there are two recommended vaccines to help prevent pneumococcal dis- ease in older adults: the Pneumovax 23 and the Prevnar 13. The most common presentations of pneumococcal disease are pneumonia, sepsis, and meningitis. In 2014, the Advisory Committee on Immunization Practices (ACIP) recommended that the Prevnar 13 be used as a first-line immunization in person's age 65 and older who had not previously been vaccinated against pneumococcal disease, to be followed 12 months later by the Pneumovax 23. Similarly, if a patient has previously been vaccinated with Pneumovax 23, it is recommended to administer the Prevnar 13. The Prevnar 13 should be given no sooner than 6—12 months after the Pneumovax 23. The Prevnar 13 has been reported to be 45 % effective in preventing invasive
pneumococcal disease in patients over 65 [121. Prevnar 13 is a conjugate vaccine while Pneumovax 23 is a polysaccharide vaccine. Prevnar 13 protects against the 13 strains Of pneumococcus that are most frequently seen in the elderly population. The Pneumovax 23 protects against 23 strains, but seems more effective when given in a series with the Prevnar 13. The main contraindication to vaccination with Prevnar 13 is an allergy to diphtheria vaccine. Contraindication to Pneumovax is an allergic reaction to prior Pneumovax vaccination. Both vaccines can cause some swelling, redness and tenderness at the injection site that usually resolves within a week.
so here is a cheat sheet
Pneumococcus Currently there are two recommended vaccines to help prevent pneumococcal dis- ease in older adults: the Pneumovax 23 and the Prevnar 13. The most common presentations of pneumococcal disease are pneumonia, sepsis, and meningitis. In 2014, the Advisory Committee on Immunization Practices (ACIP) recommended that the Prevnar 13 be used as a first-line immunization in person's age 65 and older who had not previously been vaccinated against pneumococcal disease, to be followed 12 months later by the Pneumovax 23. Similarly, if a patient has previously been vaccinated with Pneumovax 23, it is recommended to administer the Prevnar 13. The Prevnar 13 should be given no sooner than 6—12 months after the Pneumovax 23. The Prevnar 13 has been reported to be 45 % effective in preventing invasive
pneumococcal disease in patients over 65 [121. Prevnar 13 is a conjugate vaccine while Pneumovax 23 is a polysaccharide vaccine. Prevnar 13 protects against the 13 strains Of pneumococcus that are most frequently seen in the elderly population. The Pneumovax 23 protects against 23 strains, but seems more effective when given in a series with the Prevnar 13. The main contraindication to vaccination with Prevnar 13 is an allergy to diphtheria vaccine. Contraindication to Pneumovax is an allergic reaction to prior Pneumovax vaccination. Both vaccines can cause some swelling, redness and tenderness at the injection site that usually resolves within a week.
No comments:
Post a Comment